HSV-1 infected cell proteins influence tetracycline-regulated transgene expression

Journal of Gene Medicine

Volumn 2, Issue 5, 2000, Pages 379-389

  Herrlinger, Ulrich ^a,b   Pechan, Peter A ^a   Jacobs, Andreas H ^a,c   Woiciechowski, Christian ^a,d   Rainov, Nikolai G ^a,e   Fraefel, Cornel ^a,f   Paulus, Werner ^a,g   Reeves, Steven A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f UNIVERSITY OF ZURICH   (Switzerland)

^g UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CUCUMBER MOSAIC VIRUS; HERPES; HUMAN HERPESVIRUS 1;

HERPES SIMPLEX VIRUS, TYPE 1 PROTEIN ICP4; IMMEDIATE EARLY PROTEIN; LUCIFERASE; TETRACYCLINE; VIRUS PROTEIN;

ANIMAL; ARTICLE; CERCOPITHECUS; DRUG EFFECT; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HERPES SIMPLEX VIRUS 1; IMMEDIATE EARLY GENE; METABOLISM; MUTATION; PLASMID; PROMOTER REGION; VERO CELL;

ANIMALS; CERCOPITHECUS AETHIOPS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENES, IMMEDIATE-EARLY; HERPESVIRUS 1, HUMAN; IMMEDIATE-EARLY PROTEINS; LUCIFERASES; MUTATION; PLASMIDS; PROMOTER REGIONS (GENETICS); TETRACYCLINE; TRANSCRIPTION, GENETIC; TRANSFECTION; VERO CELLS; VIRAL PROTEINS;

EID: 0034278131     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-2254(200009/10)2:5<379::AID-JGM126>3.0.CO;2-G     Document Type: Article

References (71)

1. No D, Yao TP, Evans RM. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci U S A 1996; 93: 3346-3351.
2. Suhr ST, Gil EB, Senut MC, et al. High level transactivation by a modified Bombyx ecdysone receptor in mammalian cells without exogenous retinoid X receptor. Proc Natl Acad Sci U S A 1998; 95: 7999-8004.
3. Israel DI, Kaufman RJ. Highly inducible expression from vectors containing multiple GREs in CHO cells overexpressing the glucocorticoid receptor. Nucleic Acids Res 1989; 17: 4589-4604.
4. Lu B, Federoff HJ. Herpes simplex virus type 1 amplicon vectors with glucocorticoid-inducible gene expression. Hum Gene Ther 1995; 6: 419-428.
5. Glorioso JC, Bender MA, Goins WF, et al. Herpes simplex virus as a gene-delivery vector for the central nervous system. In Viral Vectors. Kaplitt MG, ColwyAD (eds). Academic Press: New York, 1995: 1-23.
6. Rivera VM, Clackson T, Natesan S, et al. A humanized system for pharmacologic control of gene expression. Nat Med 1996; 2: 1028-1032.
7. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992; 89: 5547-5551.
8. Gossen M, Freundlieb S, Bender G, et al. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268: 1766-1769.
9. Paulus W, Baur I, Boyce FM, et al. Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J Virol 1996; 70: 62-67.
10. Hofmann A, Nolan GP, Blau HM. Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette. Proc Natl Acad Sci U S A 1996; 93: 5185-5190.
11. Lindemann D, Patriquin E, Feng S, et al. Versatile retrovirus vector systems for regulated gene expression in vitro and in vivo. Mol Med 1997; 3: 466-476.
12. Hu SX, Ji W, Zhou Y, et al. Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. Cancer Res 1997; 57: 3339-343.
13. Paulus W, Baur I, Breakefield XO, et al. Regulated expression of the diphtheria toxin A fragment gene in human tumor cells by prokaryotic transcription control elements. J Neurosurg 1997; 87: 89-95.
14. Hwang JI, Scuric Z, Anderson WF. Novel retroviral vector transferring a suicide gene and a selectable marker gene with enhanced gene expression by using a tetracycline-responsive expression system. J Virol 1996; 70: 8138-8141.
15. A-Mohammadi S, Hawkins RE. Efficient transgene regulation from a single tetacycline-controlled positive feedback regulatory system. Gene Ther 1998; 5: 76-84.
16. Ho DY, McLaughlin JR, Sapolsky RM. Inducible gene expression from defective herpes simplex virus vectors using the tetracy cline-responsive promoter system. Mol Brain Res 1996; 41: 200-209.
17. Fotaki ME, Pink JR, Mous J. Tetracycline-responsive gene expression in mouse brain after amplicon-mediated gene transfer. Gene Ther 1997; 4: 901-908.
18. Chen J, Bezdek T, Chang J, et al. A glial specific, repressible, adenovirus vector for brain tumor gene therapy. Cancer Res 1998; 58: 3504-3507.
19. Harding TC, Geddes BJ, Murphy D, et al. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nat Biotech 1998; 16: 553-555.
20. Massie B, Couture F, Lamoureux L, et al. Inducible over-expression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. J Virol 1998; 72: 2289-2296.
21. Freundlieb S, Schirra-Muller C, Bujard H. A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J Gene Med 1999; 1: 4-12.
22. Roizman B, Sears AE. Herpes viruses and their replication. In Virology, Fields BN (ed.). Raven Press: New York, 1996; 2231-2264.
23. ApRhys CMJ, Ciufo DM, O'Neill EA, et al. Overlapping octamer and TAATGARAT motifs in the VT65-response elements in herpes simplex virus immediate-early promoters represent independent binding sites for cellular nuclear factor III. J Virol 1989; 63: 2798-2812.
24. Carrozza MJ, DeLuca NA. Interaction of the viral activator protein ICP4 with TFIID through TAF250. Mol Cell Biol 1996; 16: 3085-3093.
25. Smith CA, Bates P, Rivera-Gonzalez R, et al. ICP4, the major transcriptional regulatory protein of herpes simplex virus forms a tripartite complex with TATA-binding protein and TFIIB. J Virol 1993; 67: 4676-4687.
26. Cheung P, Panning B, Smiley JR. Herpes simplex virus immediate-early proteins ICP0 and ICP4 activate the endogenous human alpha-globin gene in nonerythroid cells. J Virol 1997; 71: 1784-1793.
27. Brown CR, Nakamura MS, Mosca JD, et al. Herpes simplex virus trans-regulatory protein ICP27 stabilizes and binds to 3′ ends of labile mRNA. J Virol 1995; 69: 7187-7195.
28. Homa FL, Glorioso JC, Levine M. A specific 15-bp TATA box promoter element is required for expression of a herpes simplex virus type 1HH late gene. Genes Dev 1988; 2: 40-53.
29. Johnson PA, Everett RD. The control of herpes simplex virus type 1 late gene transcription: a TATA-box/capsite region is sufficient for fully regulated activity. Nucleic Acids Res 1986; 14: 8247-8264.
30. Everett RD. A detailed analysis of an HSV-1 early promoter: sequences involved in trans-activation by viral immediate-early gene products are not early gene specific. Nucleic Acids Res 1984; 12: 3037-3057.
31. Everett RD. Activation of cellular promoters during herpes simplex virus infection of biochemically transformed cells. EMBO J 1985; 4: 1973-1980.
32. Everett RD. Promoter sequence and cell type can dramatically affect the efficiency of transcriptional activation induced by herpes simplex type 1 and its immediate-early gene products Vmw175 and Vmw110. J Mol Cell Biol 1988; 203: 739-751.
33. Breakefield XO, Pechan P, Johnson K, et al. Herpes virus vectors. In Stem Cell Biology and Gene Therapy, Quesenberry PJ, Stein GJ, Forget B, Weissman S (eds). John Wiley: New York, NY, 1998: 201-233.
34. Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: Part II. Vector systems and applications. Neoplasia 1999; 1: 402-416.
35. Andreansky SS, He B, Gillespie GY, et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci U S A 1996; 93: 11313-11318.
36. Herrlinger U, Jacobs A, Aghi M, et al. HSV-1 vectors for gene therapy of experimental CNS tumors. In Methods in Molecular Medicine, Gene Therapy Protocols, Robbins P (ed.). Humana Press: Totowa, NJ 2000; 287-312.
37. Martuza RL, Malick A, Markert JM, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856.
38. Samaniego LA, Wu N, DeLuca NA. The herpes simplex virus immediate-early protein ICPO affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J Virol 1997; 71: 4614-4625.
39. Miyatake S, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther 1997; 4: 222-228.
40. Pechan PA, Herrlinger U, Aghi M, et al. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas. J Gene Med 1999; 1: 176-185.
41. Fraefel C, Jacoby DR, Breakefield XO. Recent developments on herpes simplex virus type 1-based amplicon vector systems. Adv Virus Res (in press).
42. Lim F, Hartley D, Starr P, et al. Generation of high-titer defective HSV-1 vectors using an IE2 deletion mutant and quantitative study of expression in cultured cortical cells. Biotechniques 1996; 20: 458-469.
43. Fraefel C, Song S, Lim F, et al. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 1996; 70: 7190-7197.
44. Saeki Y, Ichikawa T, Saeki A, et al. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 1998; 9: 2787-2794.
45. Stavropoulos TA, Strathdee CA. An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol 1998; 72: 7137-7143.
46. Johnson PA, Wang MJ, Friedmann T. Improved cell survival by the reduction of immediate-early gene expression in replication-defective mutants of herpes simplex virus type 1 but not by mutation of the virion host shutoff function. J Virol 1994; 68: 6347-6362.
47. Rice SA, Knipe DM. Genetic evidence for two distinct transactivation functions of the herpes simplex virus alpha protein ICP27. J Virol 1990; 64: 1704-1715.
48. DeLuca NA, McCarthy A, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985; 56: 558-570.
49. Samaniego LA, Webb AL, DeLuca NA. Functional interactions between herpes simplex virus immediate-early proteins during infection: gene expression as a consequence. J Virol 1995; 69: 5705-5715.
50. Goldstein DJ, Weller S. Herpes simplex virus type 1-induced ribonucleotide reductase activity is indispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62: 196-205.
51. Cai W, Schaffer PA. Herpes simplex virus type 1 ICPO plays a critical role in the de novo synthesis of infectious virus following transfection of viral DNA. J Virol 1989; 63: 4579-4589.
52. Morgenstern JP, Land H. A series of mammalian expression vectors and characterization of their expression of a reporter gene in stably and transiently transfected cells. Nucleic Acids Res 1990; 18: 1068.
53. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990; 18: 3585-3596.
54. Pechan PA, Fotaki M, Thompson RL, et al. A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors. Hum Gene Ther 1996; 7: 2003-2013.
55. Geller AI, Breakefield XO. A defective HSV-1 vector expresses Escherichia coli β-galactosidase in cultured peripheral neurons. Science 1988; 241: 1667-1669.
56. Cunningham C, Davidson AJ. A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology 1993; 197: 116-124.
57. Roemer K, Johnson PA, Friedmann T. Activity of the simian virus 40 early promoter-enhancer in herpes simplex virus type 1 vectors is dependent on its position, the infected cell type, and the presence of Vmw175. J Virol 1991; 65: 6900-6912.
58. Coen DM, Weinheimer SP, McKnight SL. A genetic approach to promoter recognition during trans induction of viral gene expression. Science 1986; 234: 53-59.
59. McKnight SL, Tijan R. Transcriptional selectivity of viral genes in mammalian cells. Cell 1986; 46: 795-805.
60. Smiley JR, Johnson DC, Pizer LI, et al. The ICP4 binding sites in the herpes simplex virus type 1 glycoprotein (gD) promoter are not essential for efficient gD transcription during virus infection. J Virol 1992; 66: 623-631.
61. Oligino T, Poliani PL, Marconi P, et al. In vivo transgene activation from an HSV-based gene therapy vector by GAL4:vp16. Gene Ther 1996; 3: 892-899.
62. Oligino T, Poliani PL, Wang Y, et al. Drug inducible transgene expression in brain using a herpes simplex virus vector. Gene Ther 1998; 5: 491-196.
63. Rice SA, Knipe DM. Gene-specific transactivation by herpes simplex virus type 1 alpha protein ICP27. J Virol 1988; 62: 3814-3823.
64. Sekulovich RE, Leary K, Sandri-Goldin RM. The herpes simplex virus type 1 alpha protein can act as a trans-repressor or a transactivator in combination with ICP4 and ICP0. J Virol 1988; 62: 4510-4522.
65. Su L, Knipe DM. Herpes simplex virus alpha protein ICP27 can inhibit or augment viral gene transactivation. Virology 1989; 170: 496-504.
66. Chapman CJ, Harris JD, Hardwicke MA, et al. Promoter-independent activation of heterologous virus gene expression by the herpes simplex virus immediate-early protein ICP27. Virology 1992; 186: 573-578.
67. Sandri-Goldin RM, Mendoza GE. A herpes virus regulatory protein appears to act post-transcriptionally by affecting mRNA processing. Genes Dev 1992; 6: 848-863.
68. Raniero DI, Stasio P, Taylor MW. Specific effect of interferon on the herpes simplex virus type 1 transactivation event. J Virol 1990; 64: 2588-2593.
69. Jamieson DRS, Robinson LH, Daksis JI, et al. Quiescent viral genomes in human fibroblasts after infection with herpes simplex virus Vmw65 mutants. J Gen Virol 1995; 76: 1417-1431.
70. Nicholl MJ, Preston CM. Inhibition of herpes simplex virus type 1 immediate-early gene expression by alpha interferon is not VP16 specific. J Virol 1996; 70: 6336-6339.
71. Miyatake SI, Iyer A, Martuza RL, et al. Transcriptional targeting of Herpes simplex virus for cell-specific replication. J Virol 1997; 71: 5124-5132.